EGFR and neoplasm: 6) Subpopulation of EpCAM-/ABCG2+ cells expressing EMT markers, indicating potential plasticity (Supplementary Figure S8D) 7) These EpCAM+/ABCG2+ cells derived xenograft growth can be inhibited by treating mice with Axitinib and Erlotinib (Supplementary Figure S8E) indicating that VEGFR1 and EGFR may be involved with the cisplatin-induced tumor stemness switch, consistent with our previous findings (9).